Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Uterine Cervical Neoplasms × niraparib × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 23 Prostatic Neoplasms 8 Breast Neoplasms 7 Fallopian Tube Neoplasms 6 Pancreatic Neoplasms 5 Neoplasm Metastasis 4 Endometrial Neoplasms 4 Neoplasms 3 Head and Neck Neoplasms 3 Glioblastoma 3 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Recurrence 2 Mesothelioma, Malignant 2 Mesothelioma 2 Melanoma 2 Lung Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Uveal Melanoma 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Triple Negative Breast Neoplasms 1 Thrombocytopenia 1 Stomach Neoplasms 1 Solid Tumor 1 Sarcoma 1

Interventions

Cisplatin 49 Paclitaxel 23 Radiotherapy 22 Carboplatin 19 Bevacizumab 18 pembrolizumab 17 Brachytherapy 14 atezolizumab 9 camrelizumab 8 Gemcitabine 8 Nivolumab 7 zimberelimab 6 Topotecan 6 Radiation 6 Docetaxel 6 Albumin-Bound Paclitaxel 6 toripalimab 5 nimotuzumab 5 dostarlimab 5 Taxes 5 Papillomavirus Vaccines 5 Drug Therapy 5 Cetuximab 5 tislelizumab 4 lenvatinib 4 durvalumab 4 Ipilimumab 4 Injections 4 Chemoradiotherapy 4 Capecitabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04068753 2026-02-10

STAR

University of Oklahoma

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡